Editor's comment: Meritable but marred

Lynn Rouse

After years of wrangling over questions of fairness, viability and necessity - not to mention extended periods in political limbo - this week we finally witnessed the creation of an insurance fund of last resort for mesothelioma victims.

For the first 10 years of the government scheme, entirely funded by employers' liability insurers, £300m will be set aside for those unable to trace the liable employer or EL insurer.

The employer

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@postonline.co.uk or view our subscription options here: http://subscriptions.postonline.co.uk/subscribe

You are currently unable to copy this content. Please contact info@postonline.co.uk to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to Insurance Post? View our subscription options

Inspecting and impressing in the gadget insurance market

Ahead of Black Friday (29 November) the latest Insurance Post Podcast explains how gadget insurers are increasingly looking at the way devices are used rather than the likelihood of the component parts ceasing to work when it comes to underwriting and claims.

Checking the price is right for insurance

Emma Ann Hughes examines how to prove the price is right of cover for different segments of consumers and observes it requires a whole lot more than just knowing the cost of delivering insurance products and services.

Gigasure CEO outlines pet and PCW plans

Ernesto Suarez, CEO of Gigasure, has told Insurance Post of the firm’s plans to be listed on multiple price comparison websites by the end of the year, and launch a pet product.

Most read articles loading...

You need to sign in to use this feature. If you don’t have an Insurance Post account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here